



Gene Therapy Treatment for Haemophilia

[Source: TH](#)

Indian scientists have developed a novel [gene therapy](#) for haemophilia A, offering a **one-time treatment to replace frequent clotting factor injections**.

- In a trial at Christian Medical College, Vellore, five patients have been free of bleeding episodes for over a year.
- Haemophilia A is a **genetic disorder** caused by **insufficient Factor VIII**, preventing **proper blood clotting**. India, with 40,000 to 100,000 affected patients, has the second-largest haemophilia population globally.
 - Haemophilia A is inherited in an **X-linked recessive pattern**. Males with a **defective X chromosome have hemophilia**, while females **need two defective X chromosomes to be affected**.
 - Current treatments are lifelong and expensive, costing up to Rs 2.54 crore over ten years, making gene therapy a cost-effective alternative.
- **Gene therapy replaces defective genes in a patient's cells with healthy ones.**
- **Roctavian**, the only US Food and Drug Administration approved gene therapy, uses an **adenovirus vector to deliver a gene for Factor VIII production** in the liver but is **not approved for children**.
- The Vellore trial used a **lentivirus vector**, considered **safer and potentially suitable for children**, offering new possibilities for gene therapy in resource-constrained settings.

Read more: [World Haemophilia Day](#)

PDF Reference URL: <https://www.drishtias.com/printpdf/gene-therapy-treatment-for-haemophilia>